New drug 608 aims to ease hidden arthritis pain
NCT ID NCT07349329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called 608 in 380 adults with non-radiographic axial spondyloarthritis, a form of arthritis that causes back pain and stiffness but doesn't show up on X-rays. Participants will receive either 608 or a placebo injection to see if the drug reduces pain and inflammation. The goal is to find a new treatment option for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
608 (a drug injection)
What this could lead to
If it works, this could offer a new treatment option for people with non-radiographic axial spondyloarthritis to control pain and inflammation.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS, NON-RADIOGRAPHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 01
Beijing, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact